TB-VIR is a European
research network (Collaborative Project) coordinated by the National Center for Scientific Research (CNRS, Dr Olivier Neyrolles, Toulouse - France)and supported by the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme.
To download TB-VIR presentation leaflet, please click here
At the end of its first year
of activity, the TB-VIR consortium has obtained some major results in each arm of the programme. To know more about TB-VIR progresses, please visit "Our activities" page.
Context
Tuberculosis
(TB) is one of the major diseases pointed by the 8th Target of the United
Nation Millenium Development Goals which aims to "have halted by 2015 and
begun to reverse the incidence of malaria and other major diseases". Indeed, despite tremendous efforts to fight this
disease, TB remains a major health problem worldwide and particularly in
low-income developing countries. Despite the great
advances in the prevention and treatment of infectious diseases, respiratory
infections remain the most frequent cause of childhood morbidity and mortality
worldwide. Although licensed vaccines targeting several of these diseases exist
and are widely used, respiratory pathogens still cause more than four million
deaths per year. Most of these deaths occur in young children. For many respiratory
pathogens no satisfactory vaccine is available. For others, classical
parenteral immunisation remains insufficiently effective.
Tuberculosis
causes over 1.5 million deaths annually worldwide, and up to one third of the
global population is estimated to carry latent Mycobacterium tuberculosis
infection.
Meet us at ECCMID 21th symposium, in Milano (Italy)
TB-VIR latest news and results will be presented on a poster at the "European Network Corner" during the 21st ECCMID International Symposium.
TB-VIR holds its closure private meeting in Toulouse on March 18th, 2011
Three years after its launch, TB-VIR has accomplished major
progresses towards its objectives. This meeting will give the opportunity to the partners involved
to discuss their latest results and future prospects.
